A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus

Botfield, Hannah F; Uldall, Maria S; Westgate, Connar S J; Mitchell, James L; Hagen, Snorre M; Gonzalez, Ana Maria; Hodson, David J; Jensen, Rigmor H; Sinclair, Alexandra J

Link to publication on Research at Birmingham portal

1 **A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of**

2 **hydrocephalus**

3

4

5 **Authors:** Hannah F. Botfield[1,2,†], Maria S. Uldall[3,†], Connar S.J. Westgate[1,2], James L.

6 Mitchell[1,2,4], Snorre M. Hagen[3], Ana Maria Gonzalez[5] David J. Hodson[1,6], Rigmor H. Jensen[3],

7 Alexandra J. Sinclair[1,2,4,*]

8

9 **Affiliations:**

10 [1]Institute of Metabolism and Systems Research, University of Birmingham, Edgbaston, B15

11 2TT, UK.

12 [2]Centre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, B15 2TH,

13 United Kingdom

14 [3]Danish Headache Center, Clinic of Neurology, Rigshospitalet-Glostrup, University of

15 Copenhagen, Nordre Ringvej 69, 2600 Glostrup, Denmark

16 [4]Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, B15

17 2TH, United Kingdom

18 [5]Institute of Inflammation and Ageing, University of Birmingham, Edgbaston, B15 2TT, UK.

19 [6]COMPARE University of Birmingham and University of Nottingham, Midlands, UK.

20 *Corresponding author: Dr Alexandra Sinclair, a.b.sinclair@bham.ac.uk

21 [†]Joint first authors

22

23

24

25 **Overline:**

One sentence summary:

GLP-1R agonists show promise as a therapeutic agent to lower intracranial pressure in rodents.

Abstract

Current therapies for reducing raised intracranial pressure (ICP) under conditions such as idiopathic intracranial hypertension or hydrocephalus have limited efficacy and tolerability. Thus, there is a pressing need to identify alternative drugs. Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat diabetes and promote weight loss but have also been shown to affect fluid homeostasis in the kidney. Here, we investigated whether exendin-4, a GLP-1R agonist, is able to modulate cerebrospinal fluid (CSF) secretion at the choroid plexus and subsequently reduce ICP in rats. We used tissue sections and cell cultures to demonstrate expression of GLP-1R in the choroid plexus and its activation by exendin-4, an effect blocked by the GLP-1R antagonist exendin 9-39. Acute treatment with exendin-4 reduced $Na^+ K^+$ ATPase activity, a key regulator of CSF secretion, in cell cultures. Finally, we demonstrated that administration of exendin-4 to female rats with raised ICP (hydrocephalic) resulted in a GLP-1R-mediated reduction in ICP. These findings suggest that GLP-1R agonists can reduce ICP in rodents. Repurposing existing GLP-1R agonist drugs may be a useful therapeutic strategy for treating raised ICP.

Introduction

50   Elevated intracranial pressure (ICP) is caused by alterations in the volume of either cerebral

51   blood, cerebrospinal fluid (CSF) or brain tissue. CSF volume is tightly regulated and depends

52   on the balance between CSF secretion, which is modulated predominantly by the choroid

53   plexus, and drainage through the arachnoid granulations and lymphatic (*1*). Reducing CSF

54   volume, by either CSF drainage or decreasing CSF secretion is used therapeutically to lower

55   ICP (*2, 3*) in conditions characterized by raised ICP such as idiopathic intracranial

56   hypertension and hydrocephalus.

57   In the choroid plexus, CSF is secreted by the choroid plexus epithelial (CPe) cells, and

58   is driven by net movement of sodium ions (Na^+) from the blood into the cerebral ventricles.

59   This creates an osmotic gradient, which drives water transport into the cerebral ventricles.

60   There are numerous ion channels involved in this process, but the apical Na^+ K^+ ATPase that

61   pumps Na^+ into the ventricles is the most important of these channels and represents the rate

62   limiting step (*4, 5*). Specific inhibition of the Na^+ K^+ ATPase with ouabain, reduces CSF

63   secretion by 70-80% (*6*). As such, the CPe cells function akin to inverted renal proximal tubule

64   epithelial cells with an analogous mechanism of fluid transport (*7, 8*).

65   The incretin glucagon-like peptide-1 (GLP-1), is a gut peptide secreted by the distal

66   small intestine in response to food intake (*9*). GLP-1 stimulates glucose-dependent insulin

67   secretion and inhibits glucagon release, lowering blood glucose (*10*). In addition, GLP-1 is

68   synthesized in neurons of the nucleus tractus solitarius, which project to the hypothalamus (*11*)

69   and promote satiety and weight loss (*12-14*). GLP-1 signals through the GLP-1 receptor (GLP-

70   1R), a class-B G protein-coupled receptor expressed in selected cell types within the central

71   nervous system including the hypothalamus, hippocampus, olfactory cortex, circumventricular

72   organs, hindbrain and choroid plexus (*15-17*).

73   GLP-1 also has effects on renal proximal tubule Na^+ secretion, reducing Na^+

74   reabsorption and increasing diuresis (*18*). Here, GLP-1R activation stimulates the conversion

3

75 of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP) by adenylate

76 cyclase. cAMP activates protein kinase A (PKA), which inhibits the Na^+ H^+ exchanger, thereby

77 preventing Na^+ reabsorption into the bloodstream (*18*). The diuretic actions of incretins have

78 led to investigation of their use as antihypertensive agents (*19*). Similar to its activity in the

79 kidney, we hypothesize that GLP-1 also modulates Na^+ transport and subsequently fluid

80 movement at the choroid plexus. We propose that GLP-1R activation may inhibit the basal Na^+

81 H^+ exchanger through cAMP-dependent PKA activation, thus impeding the Na^+ K^+ ATPase-

82 dependent secretion of CSF. Stabilized GLP-1 mimetics are widely used to treat diabetes and

83 obesity, and therefore could be repurposed for treating raised ICP.

84   In the present study, we used tissue sections and CPe cell cultures to assess the

85 localization and distribution of the GLP-1R in rat and human choroid plexus and determined

86 the effects of GLP-1R stimulation on CSF secretion. Furthermore, we conducted in vivo

87 studies to evaluate the effects of GLP-1R agonists on ICP in a hydrocephalus rat model with

88 raised ICP.

89

90 **Results**

91

92 *GLP-1R expression in human choroid plexus tissue*

93 Immunohistochemical analysis using haematoxylin and eosin staining confirmed that human

94 donor tissue comprised the choroid plexus, demonstrating choroid plexus morphology

95 including a cuboidal CPe cell monolayer resting on a basement membrane, the underlying

96 interstitial tissue and capillary vessels (**Fig. 1A**). *GLP-1R* mRNA expression in five human

97 choroid plexus samples was compared to known commercially available GLP-1R-positive

98 tissues (pooled samples; see methods for source details). Human pancreas had the highest

99 expression of *GLP-1R* mRNA, with heart and ovary having the least. Human choroid plexus

100   showed *GLP-1R* mRNA expression (**Fig. 1B**). To determine the localization of the receptor

101   protein, paraffin embedded human choroid plexus sections were immunostained with a specific

102   monoclonal antibody to human GLP-1R previously validated in human and monkey tissue (*20,*

103   *21*). Based on the morphology of the choroid plexus, GLP-1R positive staining was detected in

104   CPe cells (**Fig. 1C-F**). Together, these studies demonstrate that the human choroid plexus

105   expresses GLP-1R mRNA and protein.

106

107   *Exendin-4 treatment of whole rat choroid plexus in vitro*

108   Given the lack of validated antibodies against rodent GLP-1R, we instead incubated whole rat

109   choroid plexus in vitro with a fluorescently tagged GLP-1R agonist, exendin-4 (FLEX), to

110   demonstrate the presence of the receptor in the choroid plexus. After 15 minutes of 1µM FLEX

111   incubation, only a few CPe cells were positive for FLEX within the cytoplasm (**Fig. 2A**).

112   However this increased by 30 minutes (**Fig. 2A**). In both cases, GLP-1R appeared to localize

113   predominantly in the cytoplasm, consistent with agonist-induced receptor internalization and

114   trafficking, most likely via endosomes (*22*). The GLP-1R antagonist exendin 9-39 (1µM)

115   reduced the number of FLEX-positive cells within the choroid plexus (**Fig. 2A**), suggesting

116   specific binding of the FLEX ligand to GLP-1R.

117   Next, we determined *Glp-1r* mRNA expression in whole rat choroid plexus tissue after

118   incubation with 100nM exendin-4. Incubation of the rat choroid plexus with exendin-4 for 3

119   hours showed an increase in *Glp-1r* mRNA compared to artificial CSF (3.21 ± 0.70 fold,

120    $P<0.01$), with a return to baseline at 6 hours (0.78 ± 0.12 fold) (**Fig 2B**). There was also a

121   small but detectable increase in $Na^+ K^+$ *atpase* mRNA expression after 3 hours of exendin-4

122   treatment compared to incubation with artificial aCSF (1.82 ± 0.28 fold; $P<0.05$), which again

123   returned to baseline at 6 hours (0.97 ± 0.21 fold) (**Fig. 2C**). The expression of other channels

124 and transporters involved in CSF secretion, including the water channel aquaporin 1 (*Aqp1*)

125 and the $Na^+ H^+$ exchanger (*Nhe1*), were not altered after exendin-4 treatment (**Fig. 2D, E**).

126

127 *Exendin-4 treatment increases cAMP and reduces $Na^+ K^+$ ATPase activity*

128 To explore further the effects of exendin-4 on the choroid plexus, monolayers of rat CPe cells

129 were grown in culture. These CPe cells were characterized using antibodies against specific

130 identity markers and were shown to be similar to their in vivo counterparts (**Fig. S1A**),

131 including the expression of *Glp-1r* mRNA (**Fig. S1B**). To determine the effect of exendin-4 on

132 GLP-1R signaling, cAMP generation was assessed using two enzyme immunoassay systems.

133 Treatment of CPe cells with exendin-4 increased cAMP compared to control (2.14 ± 0.61 fold,

134 $P<0.01$) (**Fig. 3A**) in a concentration-dependent manner, and this could be inhibited by exendin

135 9-39 (**Fig. 3B**). Forskolin, an adenylate cyclase activator, was used as a positive control to

136 maximally stimulate cAMP production (**Fig 3A-B**) (5.30 ± 0.74 fold compared to control).

137   The role of GLP-1R signaling in CSF secretion was assessed in rat CPe cell cultures by

138 measuring $Na^+ K^+$ ATPase activity (proposed as a marker of CSF secretion from the choroid

139 plexus) (*6*). Exendin-4 treatment reduced $Na^+ K^+$ ATPase specific phosphate production

140 compared to control ($39.3 \pm 9.4\%$, $P<0.05$) (**Fig. 3C**). In addition, inhibition of PKA with PKI-

141 16-22-amide (PKI) abolished the exendin-4-induced reduction in $Na^+ K^+$ ATPase activity (95.4

142 $\pm 17.6\%$, $P<0.05$) (**Fig. 3C**).

143

144 *Exendin-4 treatment reduces ICP in conscious rats*

145 To establish whether exendin-4 was able to modulate ICP in vivo, healthy female adult rats

146 were implanted with an ICP monitor (Day 0) before receiving daily subcutaneous (SC)

147 injections of either saline or 20 µg/kg exendin-4 for 5 days (day 2-6). ICP was measured before

148 and after the SC injection on days 2, 4 and 6 (**Fig. 4A**). Examples of the ICP traces are shown

149   in **Fig. 4B**. On the first day of treatment (day 2), exendin-4 significantly reduced ICP 10

150   minutes after the SC injection; by 30 minutes ICP was $65.2 \pm 6.6\%$ of baseline compared to

151     $91.0 \pm 3.9\%$ of baseline in saline-treated rats (P<0.01) (**Fig. 4C**). A similar drop in ICP was

152   observed on day 4 ($50.4 \pm 6.9\%$ of baseline; P<0.001) and day 6 ($54.5 \pm 8.2\%$ of baseline;

153   P<0.001), 30 minutes after exendin-4 administration (**Fig. 4D-E**).

154   In addition to reducing ICP immediately after treatment, exendin-4 had a cumulative

155   effect on reducing ICP. Exendin-4 caused a significant reduction in ICP measured pre-dose on

156   day 2 (baseline, 100%) to day 4 ($79.3 \pm 7.3\%$; P<0.05) and day 6 ($72.5 \pm 5.6\%$; P<0.01) (**Fig.**

157   **4F**), which was not observed in saline-treated rats (day 2, baseline 100%; day 4, $95.5 \pm 13.6\%$;

158   day 6, $105.3 \pm 12.5\%$; **Fig. 4G**).

159   As there is evidence that weight loss can alter ICP (*23*), weights were monitored over

160   the treatment period. Whilst both saline- and exendin-4-treated rats lost weight during

161   treatment (P<0.05), there was no significant difference between the groups at any time point

162   (**Fig. 4H**). In the saline group, weight change correlated with alterations in ICP (r=0.710,

163   P=0.032), although no relationship was detected for the exendin-4 treatment group (r=-0.300,

164   P=0.552) (**Fig. 4I**).

165   The effect of SC administration of 20 µg/kg exendin-4 on blood and CSF pH and CSF

166   electrolytes was analyzed 60 minutes post-treatment. Exendin-4 maintained normal blood pH

167   (7.35 ± 0.01; **Fig. 4J**), however, it caused a reduction in CSF pH (7.41 ± 0.03; P<0.05)

168   compared to saline (blood pH 7.35 ± 0.03, CSF pH 7.61 ± 0.07) (**Fig. 4K**). CSF Na^+

169   concentration remained unaltered (saline, 150.3 ± 0.9; exendin-4, 150.3 ± 0.6) (**Fig. 4L**),

170   whereas the concentration of Cl^- ions in the CSF was reduced in the exendin-4 group (117 ± 0.5

171   mmol/L; P<0.05) compared to the saline group (123.8 ± 0.9 mmol/L) (**Fig. 4M**). Exendin-4

172   treatment also increased the concentration of Ca^{2+} ions in the CSF (1.09 ± 0.01, P>0.05)

173   compared to saline (1.03 ± 0.02) (**Fig. 4N**).

7

174

Exendin-4 acts via GLP-1R in the brain to reduce ICP in rats

To assess whether the reduction in ICP was specific to the brain, exendin-4 was injected into the lateral ventricle through an intracerebroventricular (ICV) cannula in anesthetized rats. ICV delivery of exendin-4 reduced ICP over time, which was significantly different from baseline at 15 minutes (68.9 ± 6.4%, P<0.05). ICV delivery of saline also reduced ICP over time (technical effect due to the ICV cannula itself reducing ICP), and this was significantly different from baseline at 50 minutes (74.5 ± 7.9%, P<0.05). Over the 60 minutes of ICP measurement, ICV delivery of exendin-4 significantly reduced the area-under-the-curve (AUC) of ICP compared to saline delivered via the same route (3852 ± 397 versus 4974 ± 262 AUC, P<0.05) (**Fig. 4O**). To determine if the effects of exendin-4 on ICP were mediated by the GLP-1R, the antagonist exendin 9-39 was continuously infused (4 µg/hour) into the lateral ventricle for 2 days prior to SC administration of either saline or 20 µg/kg exendin-4. SC injection of exendin-4 (ICV saline + SC exendin-4) lowered ICP (P<0.0001) compared to a SC injection of saline with ICV delivery of exendin 9-39 (ICV exendin 9-39 + SC saline; **Fig. 4P**). Central ICV exendin 9-39 infusion decreased the ICP-lowering effect of SC exendin-4 at 5 minutes (ICV exendin 9-39 + SC exendin-4 96.7 ± 13.7% vs ICV saline + SC exendin-4 65.7 ± 8.3%, P<0.001) (**Fig. 4P**). These data suggest that exendin-4 in part exerts its effects on ICP via the GLP-1R signaling pathway in the brain.

Exendin-4 reduces ICP in a dose-dependent manner and the effects last for 24 hours

Rats were treated subcutaneously with 1, 3 and 5 µg/kg exendin-4 to determine whether exendin-4 reduces ICP at lower concentrations. At 60 minutes 1, 3 and 5 µg/kg exendin-4 significantly reduced ICP to 79.0 ± 7.0% of baseline (P<0.05), 69.9 ± 8.8% of baseline (P<0.0001) and 60.6 ± 3.6% of baseline (P<0.0001), respectively, compared to saline (97.2 ±

199   2.5% of baseline) (**Fig. 5A-B**). Five µg/kg exendin-4 showed the greatest reduction in ICP and

200   the effect was still present 3 hours after the treatment (P<0.001). Conversely, in 1 and 3µg/kg

201   exendin-4 groups ICP had returned to baseline by 3 hours (**Fig. 5C**).

202   Alterations in mRNA and protein expression of GLP-1R and molecules involved in CSF

203   secretion were assessed in the choroid plexus of rats 3 hours after treatment with 1, 3 and 5

204   µg/kg exendin-4. *Glp-1R* and *Na$^+$ K$^+$ atpase* mRNA expression was not altered by exendin-4

205   treatment (**Fig. 5D-E**). Conversely, there was a 2-fold increase in the amount of *Aqp1* mRNA

206   in the 5 µg/kg exendin-4 treatment group (P<0.05) (**Fig. 5F**), and a 4-fold increase in the

207   amount of *Nhe1* mRNA expression in the 1 µg/kg exendin-4 treatment group (P<0.05) (**Fig.**

208   **5G**). Although no significant changes were observed in *Na$^+$ K$^+$ atpase* mRNA expression,

209   there was a small increase in Na$^+$ K$^+$ ATPase protein in the 5 µg/kg exendin-4 treatment group

210   (2.16 ± 0.22 AU, P<0.05) (**Fig 5H-I**). Two bands were observed for the water channel

211   aquaporin 1 (AQP1), representing the glycosylated (top band) and non-glycosylated (bottom

212   band) forms of AQP1 (**Fig. 5H**). The total amount of AQP1 protein was slightly reduced by 1

213   and 3 µg/kg exendin-4 treatment but not with the higher 5 µg/kg exendin-4 dose (1 µg/kg, 1.96

214   ± 0.17 AU, P<0.05, 3 µg/kg, 1.75 ± 0.08 AU, P<0.01, 5 µg/kg, 2.75 ± 0.30 AU) (**Fig. 5J**). The

215   ratio of glycosylated AQP1 to non-glycosylated AQP1 was increased after 1 and 3 µg/kg

216   exendin-4 treatment but not after 5 µg/kg exendin-4 treatment (1µg/kg , 0.97 ± 0.06 AU,

217   P<0.05, 3 µg/kg, 1.08 ±0.06 AU, P<0.01, 5 µg/kg, 0.81 ± 0.08 AU) (**Fig. 5K**). Glycosylation is

218   important for intracellular trafficking and protein stability, making proteins more resistant to

219   proteolysis (*24*), therefore these data suggest that exendin-4 may lower AQP1 through

220   enhanced degradation of the non-glycosylated AQP1.

221   The effect of 5 µg/kg exendin-4 was monitored for 24 hours in healthy rats to determine its

222   duration of action. A single SC injection of 5 µg/kg exendin-4 maintained lower ICP compared

223   to saline over 24 hours and returned to the pre-dose ICP baseline at 24 hours (1 hour, 60.2 ±

224   3.5%, P<0.0001, 3 hours, 71.3 ± 3.7%, P<0.001, 6 hours, 70.3 ± 4.0%, P<0.0001, 12 hours,

225   88.9 ± 16.6%, P<0.01, 24 hours, 100.3 ± 14.3%, P<0.01) (**Fig. 6A**). Effects on weight and food

226   and water intake were also noted in relation to changes in ICP over 24 hours. Although

227   exendin-4 caused a greater reduction in weight at 3 and 6 hours (**Fig. 6B**), there were no

228   differences between food or water intake at any time point between exendin-4-treated and

229   saline-treated rats (**Fig. 6C-D**). *Glp-1R*, *Na$^+$ K$^+$ atpase* and *Nhe1* mRNA expression did not

230   change over the 24 hour period (**Fig. 6E-F,H**). As shown previously, 5 µg/kg exendin-4

231   increased *Aqp1* mRNA expression at 3 hours compared to saline, although this was not

232   observed at any other time point (**Fig. 6G**). There were also no significant changes in the

233   amount of Na$^+$ K$^+$ ATPase or AQP1 protein over the 24 hour time period (**Fig. 6I-L**).

234

235   *Exendin-4 treatment reduces ICP in a rodent model of raised ICP*

236   To determine the efficacy of exendin-4 to reduce ICP under conditions of raised ICP, a well-

237   characterized kaolin model of hydrocephalus in rats was used. Kaolin, an aluminium silicate,

238   acts as an irritant, inducing an inflammatory response with concomitant deposition of collagen

239   and dense fibrosis in areas of the subarachnoid space close to the injection site, which leads to

240   raised ICP (*25, 26*). Kaolin was injected into the cisterna magna, leading to development of

241   hydrocephalus, before implantation of the ICP monitor. ICP was recorded before and after a

242   SC injection of either saline or 20 µg/kg exendin-4 (**Fig. 7A**). The injection of kaolin

243   significantly increased baseline ICP (11.1 ± 1.3 mmHg; P<0.0001) compared to that of normal

244   rats (5.5 ± 0.4 mmHg) (**Fig. 7B**). Exendin-4 treatment significantly reduced ICP almost

245   immediately after the SC injection, and at 30 minutes was 62.6 ± 5.1% of baseline (P<0.0001)

246   compared to 105.0 ± 4.6% of baseline in saline-treated rats (**Fig. 7C**). Eight rats in the kaolin

247   group had baseline ICP values of greater than 10 mmHg and had an average baseline ICP of

248   13.7 ± 0.7mmHg. In these rats (ICP >10mmHg), the ICP values at 30 minutes were 56.6 ±

249 5.7% of baseline (n=4) in the exendin-4 treatment group compared to 106.7 ± 8.6% of baseline

250 (n=4) in the saline treatment group (**Fig. 7C**). In the rodents with elevated ICP, the ICP

251 waveform was very unstable, with the appearance of B-waves characteristic of pathologically

252 elevated ICP and a reduction in brain compliance (*27*). These were abolished in rats receiving

253 exendin-4 but not saline (**Fig. 7D**).

254

Discussion

256 The aim of the present study was to establish whether GLP-1 had a role in modulating CSF

257 secretion and ICP. We were able to demonstrate that the GLP-1R agonist exendin-4 was able to

258 reduce ICP in conscious healthy female rats and in a rat model of raised ICP. In addition, our

259 results suggest that the ICP-lowering properties of exendin-4 may occur through reduced CSF

260 secretion at the choroid plexus, implied by the reduction in Na^+ K^+ ATPase activity in CPe

261 cells. Furthermore, our data suggest that exendin-4 modulates CSF production in vitro through

262 the GLP-1R/cAMP/PKA signaling pathway.

263   Alvarez et al. (*15*) first described the presence of the GLP-1R in the rat ependyma and

264 choroid plexus by *in situ* hybridisation, but did not characterize the cellular localization of this

265 receptor. Our studies corroborate these findings and demonstrate further that *GLP-1R* mRNA

266 and protein are present in both rat and human choroid plexus. We localized the GLP-1R protein

267 in tissue sections of the human choroid plexus to the CPe cells using a monoclonal antibody,

268 and showed the presence of the receptor in the rat choroid plexus using fluorescently tagged

269 exendin-4. We note that no specific antibody exists for mouse/rat tissue so rodent tissue was

270 not examined for GLP-1R protein expression. In any case, our studies are in keeping with

271 others showing localization of the GLP-1R in monkey kidney and human GLP-1R transfected

272 cells (*20, 21*). G-protein coupled receptors undergo internalization, trafficking and

273 recycling/degradation following agonist stimulation (*28*). We speculate that such dynamics

274 may allow the GLP-1R to be stimulated from both sides of the choroid plexus (**Fig. S2A**).

275 Although GLP-1R mRNA and protein expression were in general low, it has recently been

276 shown that activation of the receptor requires femto- to picomolar concentrations of GLP-1R,

277 so even faced with low abundance, signaling would be expected in the presence of exendin-4

278 (*29*).

279   We successfully cultured monolayers of rat CPe cells, which we used as an in vitro cell

280 culture model of the rat choroid plexus to assess CSF secretion. The Na^+ K^+ ATPase is

281 localized to the apical surface and is the driving force for transporting Na^+ ions from the

282 choroid plexus into the CSF against its concentration gradient. Many studies have

283 demonstrated that modulation of Na^+ K^+ ATPase expression or activity directly correlates with

284 CSF secretion (*6, 30-33*). We were able to show that exendin-4 reduces Na^+ K^+ ATPase

285 activity, suggesting reduced CSF secretion at the choroid plexus. Previous studies have shown

286 similar effects of exendin-4 on Na^+ K^+ ATPase activity in the renal system (*34*). In kidney

287 proximal tubule epithelial cells and pancreatic beta cells, GLP-1 modulates Na^+ concentration

288 through increased cAMP and PKA activation (*18, 35*). Using two different techniques,

289 exendin-4 was seen to induce a concentration-dependent rise in cAMP in the choroid plexus,

290 which was inhibited by the GLP-1R antagonist, exendin 9-39. Furthermore, a PKA inhibitor

291 blocked the effects of exendin-4 on Na^+ K^+ ATPase activity, although we acknowledge that

292 such approaches can be non-specific and further studies using specific knockout animals are

293 required. Altogether, these data indicate that the cAMP/PKA-dependent pathway may be

294 involved in the GLP-1R-mediated reduction in CSF secretion at the choroid plexus. In the

295 kidney, GLP-1R agonist treatment increases diuresis through phosphorylation of the Na^+ H^+

296 exchanger (*18, 36*). There are PKA phosphorylation sites present on both the Na^+ H^+ exchanger

297 and the Na^+ K^+ ATPase (*37*), therefore, in the choroid plexus, phosphorylation of either the Na^+

298 H^+ exchanger or the Na^+ K^+ ATPase may result in inhibition of Na^+ transport across the cells

12

299 and thus CSF production (**Fig. S2B-C**). In the choroid plexus, the Na^+ K^+ ATPase can also be

300 phosphorylated by PKC (*37*). Interestingly, GLP-1R is able to signal through the PKC pathway

301 in pancreatic beta cells (*29, 38, 39*). Therefore, the GLP-1R/PKC signaling pathway may also

302 have a role in reducing CSF secretion and warrants further investigation.

303   The key finding of this study is that subcutaneous exendin-4 treatment is able to reduce

304 ICP in vivo in normal rats and rats with raised ICP. In addition, the effect on ICP of a single

305 administration of exendin-4 lasted for 24 hours and cumulative dosing reduced the pre-dose

306 ICP. This suggests that exendin-4 may be able to maintain low ICP over a long period. This is

307 an important advance, as there are very limited specific therapeutic options to clinically reduce

308 and maintain low ICP under conditions of raised ICP. The main therapeutic agent for managing

309 chronic raised ICP is acetazolamide, a carbonic anhydrase inhibitor. However, in idiopathic

310 intracranial hypertension, acetazolamide is associated with limited efficacy and poor

311 tolerability (48% withdrawal) (*2*), and is contraindicated for use in premature infants with post-

312 haemorrhagic hydrocephalus (*40*). On the other hand, treatment with incretin mimetics is

313 generally well tolerated, with the main side effects being transient nausea, constipation and

314 diarrhea, and these drugs do not induce hypoglycemia (*41*). In patients taking the GLP-1R

315 agonist liraglutide, drug withdrawal due to side effects was only 5.4% in the cohort receiving

316 the highest dose (3mg; *12*).

317   There are, however, a number of limitations to the present study. To determine the

318 central actions of exendin-4 on ICP, we had to deliver exendin-4 directly into the brain's

319 ventricular system. The injection itself may have a direct effect on ICP and could mask any

320 changes in ICP relating to the treatment. To try to minimize these effects, we implanted an ICV

321 cannula 2 days prior to the injection. Nonetheless, as it was not possible to completely seal the

322 system, ICP showed a slight decrease in saline-treated rats. However, we were still able to

323 establish a significant reduction in ICP with exendin-4 treatment. The study design was also

limited by the lack of blinding during the intervention, although the data were analyzed by different individuals with the same outcome. ICP was monitored continuously via automated software thus removing measurement bias. It will be of interest to study in the future, prolonged dosing in a rat model of hydrocephalus. However, this will require considerable technical optimization, given that ICP is notoriously difficult to measure in such models where recordings are typically only accurate immediately before euthanasia (*42, 43*).

GLP-1R agonists also have peripheral actions that have the potential to indirectly affect ICP. Whilst incretin mimetics have been shown to acutely increase heart rate and blood pressure (*44*), hypertension would be expected to cause the opposite effect to that seen here due to increased choroid plexus permeability and fluid secretion (*45, 46*). Indeed, our data imply that the effect of exendin-4 on ICP dynamics is through central mechanisms, since ICV infusion of exendin 9-39 partially inhibited the action of SC exendin-4. Exendin 9-39 may not have fully inhibited the actions of exendin-4, since the inhibitor was infused into the ventricle rather than being given as a bolus injection. However, it is also possible that the effects of exendin-4 are not fully mediated by GLP-1R and this requires further investigation. Previous studies have also demonstrated only moderate effects on attenuating exendin-4 induced food intake suppression at early time points following ICV bolus of exendin 9-39 (*47*). Nevertheless, the central actions of exendin-4 are further supported by the fact that exendin-4 lowered CSF pH whereas blood pH remained unchanged, which is supported by other studies showing that GLP-1 does not affect blood pH (*19*). It remains unclear how the subcutaneous administration of the GLP-1R agonist exendin-4 exerts its central effects on the choroid plexus. Following subcutaneous administration, circulating exendin-4 may cross the fenestrated capillaries in the choroid plexus and stimulate the GLP-1R on the basolateral side of the CPe cells. Otherwise, it is possible that exendin-4 crossed the blood brain barrier (*48, 49*) or entered the CSF via the circumventricular organs, where it is able to stimulate the receptors on the apical surface of the

349 CPe cells. Indeed, liraglutide readily crosses into the hypothalamic arcuate nucleus (*50*), and in

350 vivo imaging studies in rodents using fluorescently-tagged ghrelin show passage of the gut

351 peptide to the same region *via* fenestrated capillaries of the median eminence (*51*). Lastly,

352 exendin-4 may stimulate vagal afferents that project to the nucleus tractus solitarius (*11*). This

353 may lead to secretion of GLP-1 through a widespread network of fibres projecting to the third

354 ventricle allowing GLP-1 to enter the CSF (**Fig. S2A**).

355 In summary, exendin-4 reduces $Na^+ K^+$ ATPase activity at the choroid plexus, implying

356 a reduction in CSF secretion, and lowers ICP in conscious rats with and without elevated ICP.

357 This work demonstrates that GLP-1R agonists may provide an alternative treatment for raised

358 ICP in conditions such as idiopathic intracranial hypertension and hydrocephalus, and warrants

359 further clinical investigation in humans.

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

Materials and Methods

377

Study design

The main aim of this study was to explore the potential of exendin-4, a GLP-1R agonist, to modulate CSF secretion and subsequently reduce ICP. Three experimental studies were performed: (i) in vitro analysis of the GLP-1R and downstream signaling pathway in human and rat choroid plexus, GLP-1R expression was determined through mRNA analysis, immunostaining of human choroid plexus tissue sections and fluorescently tagged exendin-4 binding to rat choroid plexus explants. The downsteam signaling pathway was assessed in rat CPe cell culture by measuring cAMP generation and $Na^+ K^+$ ATPase activity. In vivo studies to determine the efficacy of exendin-4 to reduce ICP were conducted in (ii) healthy rats and (iii) in a pathological model of raised ICP, a rat model of hydrocephalus. The sample size (n=4-9 per experimental group) for the in vivo studies was based on the resources equation as the effects size was unknown. Exact numbers for each experiment are included below and in the figure legends. The investigators were not blinded when conducting or evaluating the experiments and the rats were randomly assigned to the treatment and control groups.

392

Human tissue

Human choroid plexus samples were obtained from the Parkinson's UK Brain Bank at Imperial College London, under the ethical approval of the Wales Research Ethics Committee (Ref. No.

396 08/MRE09/31+5). Informed consent was obtained for the use of post mortem tissue for

397 research. Samples were stored in RNALater at -80^0C before being processed for qPCR

398 following the protocol stated in the supplementary methods. Pooled human pancreas (540023),

399 heart (540011) and ovary (540071) RNA was purchased from Agilent Technologies. Fresh

400 choroid plexus samples were fixed in 4% formaldehyde before embedding in paraffin wax.

401

402 **Experimental animals**

403 For the in vitro work, 150-200g female Sprague-Dawley rats (Charles River) were used at the

404 University of Birmingham in accordance with the Animals and Scientific Procedures Act 1986,

405 licensed by the UK Home Office and approved by the University of Birmingham Ethics

406 Committee. For the in vivo studies, which were conducted in Rigshospitalet-Glostrup, 150-

407 250g female Sprague-Dawley rats (Taconic) were housed in groups of 4, kept under a 12 hour

408 light/dark cycle with free access to food and water. All experimental procedures were approved

409 by the Danish Animal Experiments Inspectorate (license number 2014-15-0201-00256 and

410 2012-15-2934-00283). After treatments and surgical procedures, the rats were monitored daily

411 for any adverse effects. Female rats were used to ensure the results were relevant to conditions

412 such as idiopathic intracranial hypertension.

413

414 **Daily subcutaneous injection of exendin-4 in normal conscious rats.** On day 0, the epidural

415 ICP probe was implanted and the animal allowed to recover. On day 2, 4 and 6, for the ICP

416 recordings the rats were sedated with midazolam (2.5 mg/kg subcutaneous injection) in an

417 infusion cage (Instech Laboratories), which had a swirl lever arm to ensure unhindered

418 movement. A stable baseline ICP reading was recorded for around 30 minutes before the rats

419 received a SC injection of either saline (n=9) or 20µg/kg exendin-4 (n=9). ICP was recorded

420   for a further 60 minutes after which the rat was returned to its normal cage. The daily SC

421   injections of saline or exendin-4 were performed at similar times of the day for each rat.

422

423   **ICV injection of exendin-4 in anesthetized rats.** To determine whether the effects of

424   exendin-4 on ICP were due to central activity the rats were fitted with an ICV cannula at the

425   same time as the epidural ICP probe implantation and the rat allowed to recover. Subsequent

426   ICP recordings during exendin-4 treatment were done under anaesthesia. A stable baseline ICP

427   reading was recorded for around 30 minutes before the following treatments were then

428   administered ICV in a counterbalance design: (1) 1µl saline (n=8) and (2) 0.3µg/1µl exendin-4

429   (n=6). ICP was recorded for a further 60 minutes after which the rat was allowed to recover.

430   Injection treatments were separated by 2-3 days.

431

432   **Continuous ICV infusion of exendin 9-39 with SC injection of exendin-4 in conscious rats.**

433   To determine whether the effects of exendin-4 on ICP are through the GLP-1R, rats were fitted

434   with an osmotic pump attached to an ICV cannula containing either saline or exendin 9-39 at

435   the same time as the epidural ICP probe implantation. On day 2 the rats were sedated, a stable

436   baseline recorded before a SC injection of either saline or 20µg/kg exendin-4. ICP was then

437   recorded for a further 60 minutes. The rats were therefore assigned to 3 treatment groups: (1)

438   Saline filled osmotic pump with SC injection of exendin-4 (ICV saline + SC exendin-4; n=6);

439   (2) exendin 9-39 filled osmotic pump with SC injection of saline (ICV exendin 9-39 + SC

440   saline; n=5); and (3), exendin 9-39 filled osmotic pump with SC injection of exendin-4 (ICV

441   exendin 9-39 + SC exendin-4; n=6).

442

443   **Exendin-4 dose response and time course experiment.** Rats underwent the same procedure

444   as outlined in experiment 1. For the dosing experiment the rats were given either 1 (n=6), 3

445   (n=6) or 5µg/kg exendin-4 (n=6) and ICP recorded for 3 hours. For the time course experiment

446   rats were given either saline (n=18 for ICP data but only 4 were used for choroid plexus

447   analysis) and ICP recorded for 24 hours, or 5µg/kg exendin-4 and the ICP recorded for 6 (n=6),

448   12 (n=6) and 24 hours (n=12 for ICP data but only 6 were used for choroid plexus analysis).

449   After each time point the rats were killed with an overdose of euthatol and transcardially

450   perfused with ice cold PBS. The choroid plexus was then dissected, frozen immediately and

451   stored at -80ºC for qPCR and western blot analysis (described in detail in the supplementary

452   methods).

453

454   **SC injection of exendin-4 in conscious hydrocephalic rats.** We used the kaolin model of

455   hydrocephalus as our model of raised ICP. On day 0 the rats received an injection of kaolin to

456   induce hydrocephalus and the rat allowed to recover. On day 6-8 the rats were fitted with an

457   epidural ICP probe and the rat was then allowed to recover in the infusion cages still connected

458   to the transducer so that the ICP could be continuously measured overnight to establish raised

459   ICP. The following morning, after establishing the baseline ICP reading was stable, the rats

460   received a SC injection of either saline (n=6, n=4 >10mmHg) or 20µg/kg exendin-4 (n=6; n=4

461   >10mmHg). ICP was then recorded for a further 60 minutes.

462

463   **Statistical analysis**

464   Values are represented as mean and standard error of the mean (SEM). The majority of the data

465   was analyzed using GraphPad Prism software, however, the time course experiment with

466   5µg/kg exendin-4 was analyzed using SPSS due to missing data points. For the ELISA cAMP

467   analysis, the non-parametric Kruskall-Wallis test was used, and was followed by Mann-

468   Whitney test (two-tailed) with the appropriate adjustment for multiple comparisons

469   (Bonferroni). T-test or One-way ANOVA (followed by a post hoc Tukey test) was used for the

470 comparison of qPCR, western blot and Na$^+$ K$^+$ ATPase activity. Two-way ANOVA with

471 Sidak's multiple comparison test was used for the comparison of ICP between two groups over

472 a period of time. Values were considered statistically significant when P values were *P<0.05,

473 **P<0.01, ***P<0.001, ****P<0.0001. Individual level data are included in table S1.

474

475

476

477 **Supplementary Materials**

478 Supplementary Materials and Methods

479 Fig. S1. Characterisation of primary rat choroid plexus epithelial cells *in vivo* and *in vitro*.

480 Fig. S2. Suggested route for GLP-1 action at the choroid plexus

481 Table S1. Individual level data corresponding to the different figures.

482

483 **References**

484 1. L. Sakka, G. Coll, J. Chazal, Anatomy and physiology of cerebrospinal fluid. *European Annals of*
485 *Otorhinolaryngology, Head and Neck Diseases* **128**, 309-316 (2011).
486 2. A. K. Ball, A. Howman, K. Wheatley, M. A. Burdon, T. Matthews, A. S. Jacks, M. Lawden, A.
487 Sivaguru, A. Furmston, S. Howell, B. Sharrack, M. B. Davies, A. J. Sinclair, C. E. Clarke, A
488 randomised controlled trial of treatment for idiopathic intracranial hypertension. *Journal of*
489 *neurology* **258**, 874-881 (2011).
490 3. M. Wall, M. P. McDermott, K. D. Kieburtz, J. J. Corbett, S. E. Feldon, D. I. Friedman, D. M. Katz,
491 J. L. Keltner, E. B. Schron, M. J. Kupersmith, Effect of acetazolamide on visual function in
492 patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic
493 intracranial hypertension treatment trial. *Jama* **311**, 1641-1651 (2014).
494 4. P. D. Brown, S. L. Davies, T. Speake, I. D. Millar, Molecular mechanisms of cerebrospinal fluid
495 production. *Neuroscience* **129**, 957-970 (2004).
496 5. T. Speake, C. Whitwell, H. Kajita, A. Majid, P. D. Brown, Mechanisms of CSF secretion by the
497 choroid plexus. *Microscopy research and technique* **52**, 49-59 (2001).
498 6. M. Pollay, B. Hisey, E. Reynolds, P. Tomkins, F. A. Stevens, R. Smith, Choroid plexus Na+/K+-
499 activated adenosine triphosphatase and cerebrospinal fluid formation. *Neurosurgery* **17**, 768-
500 772 (1985).
501 7. M. D. Parker, E. J. Myers, J. R. Schelling, Na+-H+ exchanger-1 (NHE1) regulation in kidney
502 proximal tubule. *Cellular and molecular life sciences : CMLS* **72**, 2061-2074 (2015).
503 8. H. H. Damkier, P. D. Brown, J. Praetorius, Cerebrospinal fluid secretion by the choroid plexus.
504 *Physiological reviews* **93**, 1847-1892 (2013).
505 9. L. L. Baggio, D. J. Drucker, Biology of incretins: GLP-1 and GIP. *Gastroenterology* **132**, 2131-
506 2157 (2007).

507 10. J. E. Campbell, D. J. Drucker, Pharmacology, physiology, and mechanisms of incretin hormone
508   action. *Cell metabolism* **17**, 819-837 (2013).
509 11. P. J. Larsen, M. Tang-Christensen, J. J. Holst, C. Orskov, Distribution of glucagon-like peptide-1
510   and other preproglucagon-derived peptides in the rat hypothalamus and brainstem.
511   *Neuroscience* **77**, 257-270 (1997).
512 12. A. Astrup, S. Rossner, L. Van Gaal, A. Rissanen, L. Niskanen, M. Al Hakim, J. Madsen, M. F.
513   Rasmussen, M. E. Lean, Effects of liraglutide in the treatment of obesity: a randomised,
514   double-blind, placebo-controlled study. *Lancet* **374**, 1606-1616 (2009).
515 13. A. L. Alhadeff, H. J. Grill, Hindbrain nucleus tractus solitarius glucagon-like peptide-1 receptor
516   signaling reduces appetitive and motivational aspects of feeding. *American journal of
517   physiology. Regulatory, integrative and comparative physiology* **307**, R465-470 (2014).
518 14. A. Flint, A. Raben, A. Astrup, J. J. Holst, Glucagon-like peptide 1 promotes satiety and
519   suppresses energy intake in humans. *The Journal of clinical investigation* **101**, 515-520 (1998).
520 15. E. Alvarez, I. Roncero, J. A. Chowen, B. Thorens, E. Blazquez, Expression of the glucagon-like
521   peptide-1 receptor gene in rat brain. *Journal of neurochemistry* **66**, 920-927 (1996).
522 16. S. C. Cork, J. E. Richards, M. K. Holt, F. M. Gribble, F. Reimann, S. Trapp, Distribution and
523   characterisation of Glucagon-like peptide-1 receptor expressing cells in the mouse brain. *Mol
524   Metab* **4**, 718-731 (2015).
525 17. F. Marques, J. C. Sousa, G. Coppola, F. Gao, R. Puga, H. Brentani, D. H. Geschwind, N. Sousa, M.
526   Correia-Neves, J. A. Palha, Transcriptome signature of the adult mouse choroid plexus. *Fluids
527   Barriers CNS* **8**, 10 (2011).
528 18. L. R. Carraro-Lacroix, G. Malnic, A. C. Girardi, Regulation of Na+/H+ exchanger NHE3 by
529   glucagon-like peptide 1 receptor agonist exendin-4 in renal proximal tubule cells. *American
530   journal of physiology. Renal physiology* **297**, F1647-1655 (2009).
531 19. R. O. Crajoinas, F. T. Oricchio, T. D. Pessoa, B. P. Pacheco, L. M. Lessa, G. Malnic, A. C. Girardi,
532   Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-
533   like peptide-1. *American journal of physiology. Renal physiology* **301**, F355-363 (2011).
534 20. C. Pyke, R. S. Heller, R. K. Kirk, C. Orskov, S. Reedtz-Runge, P. Kaastrup, A. Hvelplund, L.
535   Bardram, D. Calatayud, L. B. Knudsen, GLP-1 receptor localization in monkey and human
536   tissue: novel distribution revealed with extensively validated monoclonal antibody.
537   *Endocrinology* **155**, 1280-1290 (2014).
538 21. C. Pyke, L. B. Knudsen, The glucagon-like peptide-1 receptor--or not? *Endocrinology* **154**, 4-8
539   (2013).
540 22. C. Widmann, W. Dolci, B. Thorens, Agonist-induced internalization and recycling of the
541   glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas. *The
542   Biochemical journal* **310 (Pt 1)**, 203-214 (1995).
543 23. A. Sinclair, M. Burdon, A. Ball, N. Nightingale, P. Good, T. Matthews, A. Jacks, M. Lawden, C.
544   Clarke, E. Walker, J. Tomlinson, P. Stewart, S. Rauz, Low energy diet and intracranial pressure
545   in women with idiopathic intracranial hypertension: prospective cohort study. *BMJ* **7**, 341
546   (2010).
547 24. C. M. Herak-Kramberger, D. Breljak, M. Ljubojevic, M. Matokanovic, M. Lovric, D. Rogic, H.
548   Brzica, I. Vrhovac, D. Karaica, V. Micek, J. I. Dupor, D. Brown, I. Sabolic, Sex-dependent
549   expression of water channel AQP1 along the rat nephron. *American journal of physiology.
550   Renal physiology* **308**, F809-821 (2015).
551 25. J. Hatta, T. Hatta, K. Moritake, H. Otani, Heavy water inhibiting the expression of transforming
552   growth factor-beta1 and the development of kaolin-induced hydrocephalus in mice. *J
553   Neurosurg* **104**, 251-258 (2006).
554 26. Y. Nakagawa, J. Cervos-Navarro, J. Artigas, Tracer study on a paracellular route in experimental
555   hydrocephalus. *Acta Neuropathol* **65**, 247-254 (1985).
556 27. A. Spiegelberg, M. Preuss, V. Kurtcuoglu, B-waves revisited. *Interdiscip Neurosur* **6**, 13-17
557   (2016).

558   28.   S. S. Ferguson, Evolving concepts in G protein-coupled receptor endocytosis: the role in
559   receptor desensitization and signaling. *Pharmacological reviews* **53**, 1-24 (2001).

560   29.   M. Shigeto, R. Ramracheya, A. I. Tarasov, C. Y. Cha, M. V. Chibalina, B. Hastoy, K. Philippaert, T.
561   Reinbothe, N. Rorsman, A. Salehi, W. R. Sones, E. Vergari, C. Weston, J. Gorelik, M. Katsura, V.
562   O. Nikolaev, R. Vennekens, M. Zaccolo, A. Galione, P. R. Johnson, K. Kaku, G. Ladds, P.
563   Rorsman, GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation.
564   *The Journal of clinical investigation* **125**, 4714-4728 (2015).

565   30.   M. Lindvall-Axelsson, P. Hedner, C. Owman, Corticosteroid action on choroid plexus: reduction
566   in Na+-K+-ATPase activity, choline transport capacity, and rate of CSF formation. *Experimental*
567   *brain research* **77**, 605-610 (1989).

568   31.   M. Lindvall-Axelsson, C. Nilsson, C. Owman, B. Winbladh, Inhibition of cerebrospinal fluid
569   formation by omeprazole. *Experimental neurology* **115**, 394-399 (1992).

570   32.   G. Fisone, G. L. Snyder, J. Fryckstedt, M. J. Caplan, A. Aperia, P. Greengard, Na+,K(+)-ATPase in
571   the choroid plexus. Regulation by serotonin/protein kinase C pathway. *The Journal of*
572   *biological chemistry* **270**, 2427-2430 (1995).

573   33.   M. E. Han, H. J. Kim, Y. S. Lee, D. H. Kim, J. T. Choi, C. S. Pan, S. Yoon, S. Y. Baek, B. S. Kim, J. B.
574   Kim, S. O. Oh, Regulation of cerebrospinal fluid production by caffeine consumption. *BMC*
575   *neuroscience* **10**, 110 (2009).

576   34.   S. Sancar-Bas, S. Gezginci-Oktayoglu, S. Bolkent, Exendin-4 attenuates renal tubular injury by
577   decreasing oxidative stress and inflammation in streptozotocin-induced diabetic mice. *Growth*
578   *Factors* **33**, 419-429 (2015).

579   35.   Y. Miura, H. Matsui, Glucagon-like peptide-1 induces a cAMP-dependent increase of [Na+]i
580   associated with insulin secretion in pancreatic beta-cells. *American journal of physiology.*
581   *Endocrinology and metabolism* **285**, E1001-1009 (2003).

582   36.   T. Rieg, M. Gerasimova, F. Murray, T. Masuda, T. Tang, M. Rose, D. J. Drucker, V. Vallon,
583   Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-
584   1 receptor and preserved in obese type 2 diabetic mice. *American journal of physiology. Renal*
585   *physiology* **303**, F963-971 (2012).

586   37.   A. G. Therien, R. Blostein, Mechanisms of sodium pump regulation. *American journal of*
587   *physiology. Cell physiology* **279**, C541-566 (2000).

588   38.   Y. Suzuki, H. Zhang, N. Saito, I. Kojima, T. Urano, H. Mogami, Glucagon-like peptide 1 activates
589   protein kinase C through Ca2+-dependent activation of phospholipase C in insulin-secreting
590   cells. *The Journal of biological chemistry* **281**, 28499-28507 (2006).

591   39.   M. Shigeto, K. Kaku, Are both protein kinase A- and protein kinase C-dependent pathways
592   involved in glucagon-like peptide-1 action on pancreatic insulin secretion? *Journal of diabetes*
593   *investigation* **5**, 347-348 (2014).

594   40.   C. A. Mazzola, A. F. Choudhri, K. I. Auguste, D. D. Limbrick, Jr., M. Rogido, L. Mitchell, A. M.
595   Flannery, R. Pediatric Hydrocephalus Systematic, F. Evidence-Based Guidelines Task, Pediatric
596   hydrocephalus: systematic literature review and evidence-based guidelines. Part 2:
597   Management of posthemorrhagic hydrocephalus in premature infants. *J Neurosurg Pediatr* **14**
598   **Suppl 1**, 8-23 (2014).

599   41.   T. A. Wadden, P. Hollander, S. Klein, K. Niswender, V. Woo, P. M. Hale, L. Aronne, Weight
600   maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight
601   loss: the SCALE Maintenance randomized study. *International journal of obesity (2005)* **37**,
602   1443-1451 (2013).

603   42.   W. Luedemann, D. Kondziella, K. Tienken, P. Klinge, T. Brinker, D. B. von Rautenfeld, in
604   *Intracranial Pressure and Brain Biochemical Monitoring,* M. Czosnyka, J. Pickard, P. Kirkpatrick,
605   P. Smielewski, P. Hutchinson, Eds. (Springer Vienna, 2002), vol. 81, chap. 70, pp. 271-273.

606   43.   O. Bloch, K. I. Auguste, G. T. Manley, A. S. Verkman, Accelerated progression of kaolin-induced
607   hydrocephalus in aquaporin-4-deficient mice. *J Cereb Blood Flow Metab* **26**, 1527-1537 (2006).

608 44. J. M. Barragan, R. E. Rodriguez, J. Eng, E. Blazquez, Interactions of exendin-(9-39) with the
609 effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure
610 and heart rate in rats. *Regul Pept* **67**, 63-68 (1996).
611 45. L. A. Murtha, Q. Yang, M. W. Parsons, C. R. Levi, D. J. Beard, N. J. Spratt, D. D. McLeod,
612 Cerebrospinal fluid is drained primarily via the spinal canal and olfactory route in young and
613 aged spontaneously hypertensive rats. *Fluids Barriers CNS* **11**, 12 (2014).
614 46. C. E. Johanson, J. A. Duncan, 3rd, P. M. Klinge, T. Brinker, E. G. Stopa, G. D. Silverberg,
615 Multiplicity of cerebrospinal fluid functions: New challenges in health and disease.
616 *Cerebrospinal fluid research* **5**, 10 (2008).
617 47. S. E. Kanoski, S. M. Fortin, M. Arnold, H. J. Grill, M. R. Hayes, Peripheral and central GLP-1
618 receptor populations mediate the anorectic effects of peripherally administered GLP-1
619 receptor agonists, liraglutide and exendin-4. *Endocrinology* **152**, 3103-3112 (2011).
620 48. A. J. Kastin, V. Akerstrom, Entry of exendin-4 into brain is rapid but may be limited at high
621 doses. *International journal of obesity and related metabolic disorders : journal of the*
622 *International Association for the Study of Obesity* **27**, 313-318 (2003).
623 49. A. J. Kastin, V. Akerstrom, W. Pan, Interactions of glucagon-like peptide-1 (GLP-1) with the
624 blood-brain barrier. *J Mol Neurosci* **18**, 7-14 (2002).
625 50. D. J. Hodson, R. K. Mitchell, E. A. Bellomo, G. Sun, L. Vinet, P. Meda, D. Li, W. H. Li, M. Bugliani,
626 P. Marchetti, D. Bosco, L. Piemonti, P. Johnson, S. J. Hughes, G. A. Rutter, Lipotoxicity disrupts
627 incretin-regulated human beta cell connectivity. *The Journal of clinical investigation* **123**, 4182-
628 4194 (2013).
629 51. M. Schaeffer, F. Langlet, C. Lafont, F. Molino, D. J. Hodson, T. Roux, L. Lamarque, P. Verdie, E.
630 Bourrier, B. Dehouck, J. L. Baneres, J. Martinez, P. F. Mery, J. Marie, E. Trinquet, J. A. Fehrentz,
631 V. Prevot, P. Mollard, Rapid sensing of circulating ghrelin by hypothalamic appetite-modifying
632 neurons. *Proc Natl Acad Sci U S A* **110**, 1512-1517 (2013).

633

634

635

636

637

638

639

640

641

642

643

653 **Author contributions**

654 A.S. was responsible for the study concept. H.B., A.G., D.J.H. and A.S. conceived and

655 designed the experiments; H.B. conducted the following in vitro experiments:

656 immunohistochemistry, Na^+ K^+ ATPase activity assay, cAMP assay, rat qPCR and western

657 blot, and FLEX analysis); C.W. performed human qPCR and cAMP assays; A.G. M.U. and

658 J.M contributed to the immunohistochemistry data; H.B., M.U. J.M. and S.H. performed the

659 ICP recordings; H.B. and M.U. analyzed the data; H.B., M.U., A.G., D.J.H., R.J and A.S co-

660 wrote the manuscript and all authors reviewed the final version.

661

662 **Competing interests**

663 A.S. holds patent # PCT/GB2015/052453 related to this work entitled "elevated intracranial

664 pressure treatment". R.J. has given lectures for Pfizer, Berlin-Chemie, Norspan, Merck and

665 Autonomic Technologies and has been a member of the advisory boards of Autonomic

666 Technologies, Medotech and ElectroCore.

667

668

669

670

Figure legends

Fig. 1. GLP-1R expression in post-mortem human choroid plexus tissue in vitro. (A)

Representative image of haematoxylin and eosin staining of human choroid plexus tissue

section demonstrating classic choroid plexus morphology. **(B)** The histogram shows *GLP-1R*

mRNA expression in human pancreas (n=1), heart (n=1), ovary (n=1) and choroid plexus

(n=5). **(C-D)** Representative images of GLP-1R staining of paraffin-embedded human choroid

plexus counterstained with haemotoxylin. Sections were incubated without primary antibody

(C) and with the human GLP-1R antibody MAb 3F52 **(D)**. **(E-F)** High magnification of the

boxed regions shown in C and D respectively. Scale bars, 100μm, BV – blood vessel and CPe

– choroid plexus epithelial cell.

Fig. 2. Expression of GLP-1R after treatment with exendin-4 in rat choroid plexus in

vitro. **(A)** Representative images of rat choroid plexus after treatment with artificial CSF

(aCSF) as control or fluorescently labelled exendin-4 (FLEX) in the presence or absence of the

GLP-1R antagonist exendin 9-39. DAPI (blue) was used as a nuclear marker; scale bar, 50μm

(insert, 25μm). **(B-E)** The histograms represent the fold change in mRNA expression of *Glp-*

1r **(B)**, *Na$^+$ K$^+$ atpase* **(C)**, *Aqp1* **(D)** and *Nhe1* **(E)** (aCSF n=6; 3hr n=7, 6hr n=7) *P<0.05,

**P<0.01; ANOVA with Tukey's multiple comparisons test.

Fig. 3. Effect of exendin-4 treatment on cAMP and Na$^+$ K$^+$ ATPase activity in CPe cells.

(A-B) The histograms represent the amount of cAMP generated after incubation with control,

exendin-4 with and without 1μM exendin 9-39 and forskolin (positive control) using two

different methods of cAMP detection (A - control n=8, exendin-4 n=8, Forskolin n=5, B -

Fig. 4. Effect of exendin-4 on ICP in healthy conscious rats. (A) Overview of the experimental design in normal rats. Rats were fitted with an epidural ICP probe and allowed to recover. Treatment was given daily for 5 days and ICP was recorded on days 2, 4 and 6, before and after the rats received a subcutaneous (SC) injection of either saline (n=9) or 20µg/kg exendin-4 (n=9). **(B)** Example ICP traces of saline (*blue*) and exendin-4 (*red*) treatment. Spikes in the trace represent when the animal was moving (*) and accurate recording of ICP was confirmed by the response to jugular vein compression. **(C-E)** Line graphs showing the percentage of baseline ICP after SC injection of either saline or exendin-4 on day 2 **(C)**, day 4 **(D)** and day 6 **(E)**. **(F-G)** Histograms showing the pre-dose and 60 minutes post treatment ICP values (% of baseline on day 2) on days 2, 4 and 6 for exendin-4 **(F)** and saline **(G)**. **(H)** Line graph of the % change in weight from day 2 (start of treatment) showing that both saline and exendin-4 treated rats lost weight but there was no significant difference between the groups on day 4 or 6. **(I)** Scatter plot of weight change (g) vs ICP change (mmHg) in the saline (*blue* n=4) and exendin-4 (*red* n=5) groups. **(J-N)** Histograms showing blood pH **(J)** and CSF pH **(K)**, and the concentration of Na$^+$ **(L)** Cl$^-$ **(M)** and Ca^{2+} **(N)** in the CSF, 60 minutes after a SC injection of either saline or 20µg/kg exendin-4. **(O)** ICP was measured before and after a 1µl intracerebroventricular (ICV) injection of either saline (n=8) or 0.3µg exendin-4 (n=6). **(P)**

26

Exendin 9-39 was continually infused (4μg/μl/hr) into the lateral ventricle (ICV) and ICP was measured before and after a SC injection of either 20μg/kg exendin-4 (ICV exendin 9-39 + SC exendin-4, n=6) or saline (ICV exendin 9-39 + SC saline, n=5) and compared to continuous saline infusion (ICV Saline + SC exendin-4, n=6). *P<0.05, **P<0.01, ***P<0.001; (C-H, O-P) Two way ANOVA with Sidak's multiple comparison test; (J-N) T-test (two-tailed).

Fig. 5. Effects of different doses of exendin-4 on ICP, mRNA and protein expression in healthy conscious rats. (A-B) Dose-response of exendin-4's effects on ICP following SC administration of 1 (n=6), 3 (n=6), 5 (n=23) and 20 μg/kg (n=9) exendin-4 compared to saline (n=18) at 30 and 60 minutes. **(C)** Line graph showing the percentage of baseline ICP after treatment with 1, 3 or 5μg/kg exendin-4 measured over 3 hours. **(D-G)** The histograms show *Glp-1R* **(D)**, Na^+ K^+ *atpase* **(E)**, *Aqp1* **(F)** and *Nhe1* **(G)** mRNA expression in the rat choroid plexus after saline treatment (n=4) or treatment with 1 (n=5), 3 (n=6), 5 μg/kg (n=6) exendin-4. **(H)** Representative western blots and **(I-K)** semi-quantitative protein analysis for **(I)** Na^+ K^+ ATPase (112kDa) and **(J)** total AQP1, either non-glycosylated (NG, 29kDa) or glycosylated (G, 35kDa); β-actin (42kDa) loading control. **(K)** Histogram shows the ratio of G to NG AQP1. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001. (B-C) Two-way ANOVA with Sidak's multiple comparison test; (D-G and I-K) ANOVA with Tukey's multiple comparison test.

Fig. 6. Effects of Exendin-4 time course on ICP, mRNA and protein expression in healthy conscious rats. (A) Line graph showing the percentage of baseline ICP after a single SC injection of saline (n=18) or 5μg/kg exendin-4 (n=24) measured over 24 hours. **(B-D)** Histograms showing weight loss (B), water intake (C) and food intake (D) in rats treated with saline (n=4) or 5μg/kg exendin-4 at 3 (n=6), 6 (n=6) and 24 hours (n=6). **(E-H)** Histograms representing *Glp-1r* **(E)**, Na^+ K^+ *atpase* **(F)**, *Aqp1* **(G)** and *Nhe1* **(H)** mRNA expression in the

746   rat choroid plexus after treatment with saline (n=4) and 5µg/kg exendin-4 at 3 (n=6), 6 (n=5)

747   and 24 hours (n=5). **(I)** Representative western blots and **(J-L)** semi-quantitative protein

748   analysis for **(J)** Na$^+$ K$^+$ ATPase (112kDa) and **(K)** total AQP1 either nonglycosylated (NG,

749   29kDa) or glycosylated (G, 35kDa); β-actin (42kDa) loading control. **(L)** The histogram shows

750   the ratio of G to NG AQP1. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001; (A-D) Two-way

751   ANOVA with Sidak's multiple comparison test; (E-H and J-L) ANOVA with Tukey's multiple

752   comparison test.

753

754   **Fig. 7. Effect of exendin-4 on ICP in a rat model of raised ICP (hydrocephalic). (A)**

755   Overview of the experimental plan. Kaolin was injected into the cisterna magna to induce

756   hydrocephalus. On Day 6 the ICP monitor was implanted under anaesthesia and ICP was

757   recorded overnight to allow the ICP to normalize after implantation. On Day 7, the rats were

758   given a SC injection of either saline (n=6) or 20µg/kg Exendin-4 (n=6), and ICP was recorded

759   for a further 60 minutes. **(B)** Dot plot showing the individual baseline ICP values (mmHg) for

760   the normal rats and rats injected with kaolin. The kaolin group had significantly higher baseline

761   ICP values compared to the normal group, with 8/12 rats having an ICP value of >10mmHg.

762   **(C)** Line graph showing the percentage of baseline ICP after treatment with either saline (dark

763   blue, n=6) or exendin-4 (dark red, n=6). The groups could also be further divided into those

764   with ICP >10mmHg in the saline group (light blue, n=4) and exendin-4 group (light red, n=4).

765   **(D)** Example ICP trace in a hydrocephalic rat before and after treatment with exendin-4. Before

766   treatment the rat exhibited pathological ICP B-waves (*b*), which were abolished following

767   treatment with exendin-4. **** P<0.0001; (B) T-test (two tailed); (C) Two-way ANOVA with

768   Sidak's multiple comparison test.